Pharma Marketletter

View more issues:

Articles in September, 2004 issue of Pharma Marketletter

• Massive growth potential of ChinaOs hepatitis market: study.
• US HHS issues national pandemic flu preparedness plan
• SkyePharma sees net loss fall for 1st-half 2004, as sales rise and R&D costs decrease.
• Innovative drugs and their impact on the future of oncology developments.
• Rx recycling: a better option than imports?
• Medarex' up to $510 mill deal with Pfizer
• Serono enters research and license deal with Zymogenetics which could exceed $100M.
• Canadian PM stands firm against Premiers' Pharmacare plan, ahead of health summit
• Patients need Rx choice for best treatment: study.
• Stock Commentary - Europe.
• Stock Commentary - New York
• Pharma industry's influence with UK govt is at "appropriate" levels, Parliament told.
• Schwarzenegger urges pharma over prices
• MS initiates coverage of newly-formed Sanofi-Aventis with overweight rating
• Latest research "will stimulate new migraine treatment options"
• UK Royal Society to view pharmacogenetics.
• French govt slammed over health cost "failure".
• Stock Commentary - New York.
• USP told: formularies need flexibility
• Rx cost-cutting patients do not tell docs: US study.
• US FDA head welcomes pharma trial data moves
• GSK gets off lightly with $2.5m settlement in Spitzer case
• South African High Court rejects call to throw out drug pricing regs.
• UPDATE: Ireland's Warner Chillcott mulls L1.7 billion offer from private equity group.
• Editor's views on AstaZeneca Exanta woes and Bayer/S-P deal
• Bush plan works to make health more affordable, accessible: Thompson
• PhRMA sets up clin trial data base, while NIH plans wider access to research data
• UK NICE, US CMS plan pharma data collaboration to speed R&D
• Role of Internet in Euro health delivery 2003-8.
• Cost-lowering by US Medicare enrollees who exceed Rx caps: study.
• Schwarzenegger veto threat to Rx import bills
• Sanofi posts strong first-half results
• USP Medicare Rx guide must be revised: PhRMA
• Provalis sees loss widen for full year as sales of diagnostics fall 52%.
• Stock Commentary - Europe
• Eli Lilly/Amylin's exenatide shows promise as type 2 diabetes therapy
• Stock Commentary - New York.
• World drug sales up 8% in year to July 2004
• Antisoma slashes full-year net loss
• Menarini's nebivolol shows benefit in elderly heart failure patients; SENIORS study.
• Roche's Pegasys effective in treating most difficult-to-treat form of HBV
• French reimbursable pharma spending soars 8.7% in first-half 2004
• Acambis hit by order cancellation for vaccine.
• Bayer under fire from DZ bank and press.
• New research by DSM on b-carotene
• ABPI calls for action to safeguard research/ innovation and overcoming "NICE blight"
• Tokyo pharma stocks - week to September 20.
• 11 US states fund Rx comparison project
• Warning over UK NICE Tamiflu guidance
• Bayer sees shares dip on mixed 2nd-qtr
• Tokyo pharma stocks - week to Sept 13.
• US Medicare discount Rx plan web site introduces price comparisons.
• Stock Commentary - New York
• S-P CEO calls on US Pres election winner for "innovation-friendly" environment
• New Phase III results indicate versatility of Tarceva in treating range of cancers.
• The aims of new European Union pharmaceutical rules - by Linda Horton et al.
• India "can develop new drugs for $100M, compared to global average of $1B".
• Statins to open door for more US OTC switches?
• US FDA advisers urge black box warning for antidepressant use in children.
• Letter from the Editor.
  by Barbara Obstoj
• Tokyo pharma stocks - 2 weeks to August 30.
• Pharmagene reduces 1st-half 2004 loss
• Stock Commentary - Europe
• Neuropathic pain mkt "to reach $4.83B by 2010".
• Stock Commentary - Europe
• Vernalis cuts first-half 2004 loss 50%
• Opportunities in clinical genomics assessed
• S Africa may revise Rx price regs, says Minister.
• Promise of non-toxic "magic bullet" treatment for brain tumors
• Letter from the Editor
  by Lynne Taylor
• Single UK cancer clinical trial data base urged.